Back to Agenda
Session 7: Innovation in the Pharmaceutical Sector
Session Chair(s)
Inas Chehimi
Head Regulatory Affairs - Middle East & North Africa, Novartis Pharma Services AG, United Arab Emirates
Nadine Otin
President, PHARMAREG International Consulting, France
This session will present the future of innovative medicine and its value from different perspectives: • The innovation in development of new therapies, real world evidence (RWE), novel endpoints (with regard to the development of oncology, neuroscience and diabetes, novel study designs) and benefits of the changes and cooperation between industry and regulators to regulate it; • Sharing a global overview of the research pipeline and provide more insights about what will come next, highlighting clearly the critical role of an efficient regulatory environment; • Discuss the value of innovation in the emerging market (patient quality of life, cost effectiveness, disease burden management/hospitalisation, social impact, competitiveness, etc).
Speaker(s)
Hajed M.H Hashan
Deputy of General Director, Gulf Health Council, Saudi Arabia
Frank R. Lichtenberg, PHD
Courtney C. Brown Professor of Business, Columbia University, Finance and Ecomomics Division, United States
Value of Innovation
Jeffrey Kemprecos
CGA Director-Gulf, Glaxosmithkline, United Arab Emirates
Value of Innovation and Competitiveness of the Regulatory Environment
Hend Al-Hussieny
Head, Egyptian Drug Information Centre (EDIC), Egypt
Have an account?